ClinicalTrials.Veeva

Menu

Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion

T

Texas Vascular Associates

Status

Completed

Conditions

Claudication
Rest Pain
Lower Extremity Ischemia
Atherosclerosis

Treatments

Procedure: Femoral-popliteal bypass
Procedure: Stent-graft placement

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT00962897
009-198, Viabahn #2

Details and patient eligibility

About

A retrospective review with four year followup on patients that had previously been enrolled in a study to evaluate blockages in the lower legs. The study looked at patients that had undergone a bypass of the leg from the groin to the knee area with an incision in each area using general anesthesia. These patients were compared to others who had undergone treatment with balloon dilatation and stents in the arteries in the thighs with only numbing medicine. The study was completed two years ago and was initially designed to look at outcomes at 24 months. Now the investigators are trying to go back and look at outcomes of these patients' treatment at 4 years by simply reviewing their records.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptomatic lower extremity ischemia patients treated by femoral-popliteal bypass or percutaneous covered stent graft in previous prospective study

Exclusion criteria

  • NA

Trial design

100 participants in 2 patient groups

Surgical Bypass Group
Description:
Those patients that underwent bypass of blockage in the thigh with surgery.
Treatment:
Procedure: Femoral-popliteal bypass
Stent-graft group
Description:
Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
Treatment:
Procedure: Stent-graft placement

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems